Literature DB >> 423716

Isolation and partial characterization of the neutral glycosphingolipids and gangliosides of the human heart.

G M Levis, J N Karli, S D Moulopoulos.   

Abstract

The glycosphingolipids (GSL) of the human heart muscle have been isolated from total lipids by column and thin layer chromatography and their sugars and fatty acids analyzed by gas liquid chromatography. Hearts from traffic victims were obtained at autopsy between 12 and 16 hr after death and dissected into parts (left and right ventricular walls, intraventricular septum and papillary muscle). The neutral GSL content for those parts of the hearts of two males aged 22 and one female aged 14 ranged from about 90 to 160 nmoles/g wet weight. Trihexosyl ceramide and globoside were the most abundant neutral GSL. Total ganglioside content was about 50 nmoles/g wet weight, and the most abundant gangliosides were partially characterized as GM3 and GM1; other mono-, di- and trisialogangliosides were also present. Differences in the content and composition of neutral GSL and gangliosides between the heart and other human tissues are discussed. It is concluded that the patterns of these two GSL fractions of the heart are more complex than those of the extraneural human tissues.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 423716     DOI: 10.1007/bf02533559

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  27 in total

1.  A SIMPLE AND ACCURATE MICROMETHOD FOR QUANTITATIVE DETERMINATION OF GANGLIOSIDE PATTERNS.

Authors:  K SUZUKI
Journal:  Life Sci (1962)       Date:  1964-11

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

4.  Lipid composition of lymphocyte plasma membrane from pig mesenteric lymph node.

Authors:  G M Levis; G P Evangelatos; M J Crumpton
Journal:  Biochem J       Date:  1976-04-15       Impact factor: 3.857

5.  Studies on the interaction between gangliosides, protein and divalent cations.

Authors:  K Hayashi; A Katagiri
Journal:  Biochim Biophys Acta       Date:  1974-01-23

6.  Plasma membrane glycosphingolipids (GSLs) of the human lymphoblastoid cell-line BRI 8 and differences between the GSLs of BRI 8 cells and those of peripheral lymphocytes.

Authors:  G M Levis; J N Karli; N J Crumpton
Journal:  Biochem Biophys Res Commun       Date:  1976-01-26       Impact factor: 3.575

7.  Neutral glycolipids of human kidney isolation, identification, and fatty acid composition.

Authors:  E Mårtensson
Journal:  Biochim Biophys Acta       Date:  1966-04-04

8.  Sulfatides of human kidney. Isolation, identification, and fatty acid composition.

Authors:  E Mårtensson
Journal:  Biochim Biophys Acta       Date:  1966-06-01

9.  Increase of gangliosides in atherosclerotic human aortas.

Authors:  W C Breckenridge; J L Halloran; K Kovacs; M D Silver
Journal:  Lipids       Date:  1975-04       Impact factor: 1.880

10.  Quantitative determination of the neutral glycosyl ceramides in human blood.

Authors:  D E Vance; C C Sweeley
Journal:  J Lipid Res       Date:  1967-11       Impact factor: 5.922

View more
  3 in total

1.  Gangliosides in membranes from Torpedo electric organ.

Authors:  R M Hann; J E Evans; R H McCluer; V A Eterovic
Journal:  Lipids       Date:  1996-06       Impact factor: 1.880

2.  Glycosphingolipid expression in human skeletal and heart muscle assessed by immunostaining thin-layer chromatography.

Authors:  J Müthing; M Cacić
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

3.  Expression of neutral glycosphingolipids and gangliosides in human skeletal and heart muscle determined by indirect immunofluorescence staining.

Authors:  M Cacić; J Müthing; I Kracun; U Neumann; S Weber-Schürholz
Journal:  Glycoconj J       Date:  1994-10       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.